ERI Newsletter - December 2024
Eyerising International
Introducing repeated low-level red-light therapy for myopia control. *Content for healthcare practitioners only.
It’s been another exciting month in the world of RLRL. As we get closer to the end of the year, we would love to highlight some of our newest and key developments from 2024.
Clinical Updates
MiVision webinar completed!
We had a fantastic turn-out at our recent CPD webinar on 20th November, with over 250 participants joining in from around the world! Thank you to our incredible line-up of speakers, Dr Tae Igarashi-Yokoi, Dr. FERNANDO FERNANDEZ VELAZQUEZ and Dr Aleks Stojanovic, moderator Andrew Kotsos , and the Mivision Magazine team. The questions generated were engaging and interesting, and we hope you enjoyed learning more about RLRL’s global deployment.
Don’t worry if you missed out, as the webinar recording, as well as answers to all the questions generated, will be available on the MiEducation portal in the next few weeks. If you are outside of ANZ and would like a copy of this recording, please contact info@eyerisinginternational.com.
This trial of 116 children on RLRL for 12 months examined the effect of RLRL on myopia progression as well as different choroidal parameters such as choroidal thickness and choroidal vascularity. Not only did it identify significant AL and SE control rates of 43% and 62%, but it also identified that all choroidal parameters increased significantly in the RLRL group after 12 months. Interestingly, as other studies have previously identified, 3-month results and 12-month results were strongly correlated, which suggests your 3-month follow-up appointment may be a good predictor of your patient’s 12-month outcomes!
Read our summary here or the full paper here. You can also find summaries of all our key papers of the Eyerising device here.
Did you know?
High myopia, defined typically by a SE of -5 or -6D, can be difficult to treat. There is also a limited evidence basis for most myopia treatments for highly myopic children, as these patients are often excluded from most myopia trials. A unique feature of RLRL then is that across several studies, it has shown even stronger effect in these higher degrees of myopia, even surpassing 100% efficacy with mean axial shortening across 12 months in these populations!
Read some of the key papers investigating RLRL in high myopia here and here, as well as a recent Myopia Profile article on RLRL’s effect in high myopia here.
Q&A
Q: How do I avoid rebound effect with RLRL patients?
A: Rebound effect is a common concern with myopia interventions, but has limited literature to date given the difficulty recruiting control patients and the ethical considerations in stopping myopia treatment and enabling patients to progress. There has been one study investigating the rebound effect of the Eyerising device after 1 year, which showed a modest rebound effect where the patients reverted to a similar degree of myopia progression to controls in the first year.
In clinical practice, rebound effect is less applicable as myopic patients should continue treatment until late adolescence where their myopia progression slows, and thus lesser rebound effect is observed on treatment cessation. Therefore, rather than abruptly discontinue treatment, it is recommended that treatment instead be tapered or replaced with alternative myopia treatment.
To learn more about rebound effect in RLRL, please see here an article on this topic developed in conjunction with Professor Saw Seang Mei of Singapore National Eye Centre. Thank you to Professor Saw for her valuable insights!
Looking back at 2024
Although this is only our second newsletter, it is also our final monthly newsletter for the year. It’s been a huge year for Eyerising and RLRL, and so we wanted to look back on and highlight some of our most exciting milestones:
Thank you so much as always for your engagement with us. We wish you a happy holiday season, and we will see you in 2025!
The Eyerising International Team